Drug manufacturer’s AstraZeneca and the federal government continue to joust in court as they await a crucial decision in the company’s 340B contract pharmacy lawsuit.
The two sides on Friday filed a joint status report in Astra’s lawsuit to invalidate and set aside the government’s May 17 finding that the company’s denials of 340B pricing when contract pharmacies are involved result in overcharges and violate the 340B statute. Astra and the government both have asked U.S. District Judge Leonard Stark of the District of Delaware to expedite his decision.
Drug manufacturer’s AstraZeneca and the federal government continue to joust in court as they await a crucial decision in the company’s 340B contract pharmacy lawsuit.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
